BioRestorative Therapies, Inc.

Good afternoon and welcome to the Biorestorative Therapies second quarter 2024 Investor Call. At this time, all participants are in a listen-only mode and we will open for questions following the presentation. If anyone should require operator assistance during the conference, please press star zero on your phone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Stephen Kilmer, Investor Relations. Stephen, the floor is yours.

Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on biorestorative therapy's current beliefs, assumptions, and expectations. And such statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. For details on factors, among others, that could affect expectations, see Part 1, Item 1A of our annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements, We speak only as of the date of this conference call. BioRestorative undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. On the call today representing the company are Lance Altstock, BioRestorative's chairman and chief executive officer, Francisco Silva, our vice president of research and development, and Robert Crystal, the company's chief financial officer. With that said, I'll now turn the call over to Lance.

Thank you, Steve, and good afternoon, everyone. Welcome to our second quarter quarterly conference call. On behalf of the management team and everyone at BioRestorative, I'd like to thank you for your interest in our company. And for those of you who are shareholders, we appreciate your support. We've had a very interesting and very productive first half of 2024. We're energized by the many potential value enhancing inflection points that we see ahead. As you can see from the financial results we announced today, we're very pleased with our quarterly and first half success. The team has executed well on all of our programs and with the commencement of our commercial platform and the execution of the Cartessa contract, we are also starting to make progress on a path to sustainable profitability. With that said, I'd like to turn the call over to Rob, who's going to provide a brief overview on our second quarter financial results.